GlobeNewswire·Nov 12, 2026, 4:15 PM ET

Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights

CBIO

Crescent Biopharma completed dose escalation in its Phase 1/2 ASCEND trial of CR-001 with over 125 patients dosed across the US, Europe, & South Korea.
Expansion cohorts evaluating CR-001 combined with standard of care chemotherapy are currently enrolling across multiple solid tumor types.
Initial monotherapy data for the first-line non-small cell lung cancer (NSCLC) cohort from the ASCEND trial is expected in Q1 2027.
Kelun-Biotech is conducting multiple Phase 2 studies in China combining CR-001 with sacituzumab tirumotecan (sac-TMT), with initial NSCLC data expected in mid-2027.
The partnership with Kelun-Biotech achieved nine IND clearances in 2026, with additional antibody-drug conjugate (ADC) combinations planned.
Crescent dosed the first patient in the global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, expected to enroll approximately 200 participants.
A Phase 1/2 trial combining CR-001 with CR-003 (an ITGB6-directed ADC) is expected to commence in the first half of 2027.
Crescent anticipates more than 2,000 patients will be dosed across its portfolio by mid-2027, with multiple clinical readouts scheduled for that year.
Cash & cash equivalents totaled $289.4 million as of September 30, 2026, sufficient to fund operations into the second half of 2028.
Research & development expenses for the third quarter of 2026 were $34.3 million, while general & administrative expenses were $8.7 million.
The company reported a net loss of $37.7 million for the three months ended September 30, 2026.
Crescent plans to initiate its first Phase 3 trial of CR-001 in early 2028, pending results from current expansion & monotherapy cohorts.

Company: Crescent Biopharma, Inc.
Keywords: Nasdaq:CBIO, Crescent Biopharma, Inc.